Alcohol septal ablation in drug-refractory hypertrophic obstructive cardiomyopathy patient with multiple
Ryota Sato1, Atsushi Sakamoto1, Kenichiro Suwa1
1Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Insights
Alcohol septal ablation (ASA) offers a safe and effective treatment for hypertrophic obstructive cardiomyopathy (HOCM). Careful management allows successful ASA even in high-risk patients with multiple health conditions.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) requires effective treatment, with surgical myectomy being an option for some patients.
- Alcohol septal ablation (ASA) is an alternative for HOCM patients unsuitable for surgery.
Observation:
- This case study details ASA in a high-risk HOCM patient with severe obesity, asthma, diabetes, and immunosuppression.
- Successful ASA was achieved through meticulous pre-procedural planning and intra-procedural monitoring.
Findings:
- Key management strategies included strict glycemic control, corticosteroid pre-treatment for asthma, minimal access sites, and myocardial contrast echocardiography guidance.
- These interventions were crucial for the successful outcome of ASA in a complex patient profile.
Implications:
- ASA can be a viable and safe therapeutic option for HOCM patients with significant comorbidities.
- Careful periprocedural management is essential for optimizing outcomes in challenging ASA cases.
Abstract:
Septal reduction therapy is an effective treatment for hypertrophic obstructive cardiomyopathy (HOCM). Alcohol septal ablation (ASA) is indicated for HOCM patients who are ineligible for surgical myectomy, but several tips exist for the management of high-risk patients with ASA. Here, we present a case of successful ASA in a HOCM patient with multiple comorbidities, including severe obesity, drug-refractory bronchial asthma, poorly controlled diabetes, and steroid-induced immunosuppression. Pre-procedural strict glycemic control, pre-treatment with corticosteroids for bronchospasm prevention, minimal puncture sites for device insertion, and myocardial contrast echocardiography-guided procedure contributed to the achievement of successful ASA. With careful periprocedural management, ASA is a safe and effective treatment option for drug-refractory HOCM, even in high-risk patients with multiple comorbidities.
Learning Objective:
Alcohol septal ablation can be a beneficial and safe treatment option for hypertrophic obstructive cardiomyopathy patients with multiple comorbidities, including severe obesity, drug-refractory bronchial asthma, poorly controlled diabetes, and steroid-induced immunosuppression. Detailed periprocedural management, including myocardial contrast echocardiography-guided procedure, is the key for achievement.
